CELZ-201 Administration

Biologic

CCreative Medical Technology Holdings Inc

CELZ-201 Administration is one of 20 biologic programs targeting Type 1 Diabetes. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 DiabetesActive, not recruiting

Type 1 DiabetesPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Symlin

AstraZeneca

Preclinical

3 2

Aldomet

Neurocrine Biosciences

Preclinical

2 3

Glargine

Eli Lilly

Preclinical

4 4

Pitocin

RRetrophin

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 7

Foradil

Viatris

Preclinical

1 8

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 9

Teplizumab

Sanofi

Preclinical

8 10

Mesenchymal Stem Cells

JJiangsu Topcel-KH Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Recruiting

Type 1 Diabetes

NCT05626712

Clinical

Trials by Indication[1]

Type 1 Diabetes1 trial

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

Recruiting·CCreative Medical Technology Holdings Inc·Phase 1/2·NCT05626712·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CELZ-201 Administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CELZ-201 Administration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CELZ-201 Administration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Creative Medical Technology Holdings Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: CCreative Medical Technology Holdings Inc

CELZ-201 Administration

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Type 1 Diabetes1 trial

References

Drug Info

Quick Facts

Related News